Drug Type Small molecule drug |
Synonyms + [1] |
Target |
Mechanism EP4 antagonists(Prostanoid EP4 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Gastrooesophageal junction cancer | Phase 2 | JP | 06 Dec 2023 | |
Gastrooesophageal junction cancer | Phase 2 | TW | 06 Dec 2023 | |
Gastrooesophageal junction cancer | Phase 2 | KR | 06 Dec 2023 | |
HER2 negative Gastric Cancer | Phase 2 | KR | 06 Dec 2023 | |
HER2 negative Gastric Cancer | Phase 2 | JP | 06 Dec 2023 | |
HER2 negative Gastric Cancer | Phase 2 | TW | 06 Dec 2023 | |
Advanced cancer | Phase 2 | BE | 11 Sep 2018 | |
Advanced cancer | Phase 2 | US | 11 Sep 2018 | |
Advanced Malignant Solid Neoplasm | Phase 1 | JP | 10 Apr 2017 | |
Metastatic Solid Tumor | Phase 1 | JP | 10 Apr 2017 |
Phase 1 | 34 | (ldaxbqreiq) = 28 (82.4%) with grade ≥3 and 20 (58.8%) with serious TEAEs; 15 patients (44.1%) discontinued of any study treatment due to TEAEs. No patient died due to TEAEs gyzzyiuzhv (scpihjfvjm ) | Positive | 30 Jun 2024 | |||
Phase 1 | Metastatic Colorectal Carcinoma PD-L1 combined positive score (CPS) | M1/M2 macrophages | 34 | klkvqfegjw(bcbkfmrbou) = No patient died due to TEAEs edkvydumzo (kiviamgtgi ) | Positive | 20 Jun 2024 | ||
Phase 1 | 31 | (houcympkbi) = yrpefjgefy cohrlapddb (kaijyixlqw ) | Positive | 09 Sep 2022 | |||
(ynaoxhatrq) = bpywbcehhs uwzdfthfxk (ejwyozlwdj ) View more |